Skip to main content
SpringerLink
Log in

Activity of trovafloxacin against blood isolates ofStreptococcus pneumoniae in Sweden

  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

The in vitro activity of the fluoroquinolone trovafloxacin (CP-99,219) against 257 blood isolates ofStreptococcus pneumoniae obtained from Swedish hospitals was compared with those of commonly prescribed oral antibiotics and also with those of ciprofloxacin and ofloxacin against a collection of strains resistant (n=6) or intermediately resistant (n=22) to penicillin (Pc-R). The MICs of trovafloxacin for Pc-R strains of pneumococci ranged from 0.032 to 0.25 mg/l. No difference was seen between the clinical isolates and the Pc-R strains (MIC50=0.064 mg/l and MIC90=0.125 mg/l for both collections). For the Pc-R strains, the MIC50 and MIC90 values of ciprofloxacin were 0.5 and 1 mg/l, and those of ofloxacin 2 and 4 mg/l. The incidence of resistance in the two collections (clinical isolates/Pc-R strains) was 3%/39% for tetracycline, 1%/18% for macrolides, and 3%/57% for trimethoprim/sulfamethoxazole. The results of the current study suggest that the clinical efficacy of trovafloxacin in the treatment of pneumococcal infections should be investigated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Eliopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering RC Jr: In vitro activity of CP-99,219, a new fluoroquinolone against clinical isolates of gram-positive bacteria. Antimicrobial Agents and Chemotherapy 1993, 37: 366–370.

    Google Scholar 

  2. Ito A, Hirai K, Inoue M, Koga H, Suzue S, Irikura T, Misuhashi S: In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrobial Agents and Chemotherapy 1980, 17: 103–108.

    PubMed  Google Scholar 

  3. Chin NX, Neu HC: Ciprofloxacin, a quinolone carboxylic acid compound against aerobic and anaerobic bacteria. Antimicrobial Agents and Chemotherapy 1984, 25: 329–326.

    Google Scholar 

  4. Sato K, Matsuura Y, Inoue M, Une T, Osada Y, Ogawa S, Mitsuhashi S: In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrobial Agents and Chemotherapy 1982, 22: 548–553.

    PubMed  Google Scholar 

  5. Fuchs PC, Barry AL, Jones RN, Thornsberry C: Evaluation of in vitro antibacterial activity of enoxacin: comparison with other orally absorbed antimicrobial agents, proposed disk diffusion test interpretative criteria, and quality control limits. Diagnostic Microbiology and Infectious Disease 1985, 3: 213–221.

    PubMed  Google Scholar 

  6. Hooper DC, Wolfson JS: Fluoroquinolone antimicrobial agents. New England Journal of Medicine 1991, 324: 384–395.

    PubMed  Google Scholar 

  7. Wolfson JS, Hooper DC: Fluoroquinolone antimicrobial agents. Clinical Microbiology Reviews 1989, 2: 378–424.

    PubMed  Google Scholar 

  8. Gooding BB, Jones RN: In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy 1993, 37: 349–353.

    PubMed  Google Scholar 

  9. Neu HC, Chin N-X: In vitro activity of the new fluoroquinolone CP-99,219. Antimicrobial Agents and Chemotherapy 1994, 38: 2626–2632.

    Google Scholar 

  10. Gootz TD, Brighty KE, Anderson MR, Haskell SL, Sutcliffe JA, Castaldi MJ, Castaldi MJ, McGuirk PR: In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl)naphthyridone antimicrobial. Diagnostic Microbiology and Infectious Disease 1994, 19: 235–243.

    PubMed  Google Scholar 

  11. Mufson MA:Streptococcus pneumoniae. In: Mandell GL, Douglas R, Bennett JE (ed): Principles and practice of infectious diseases. Churchill Livingstone, Edinburgh, 1990. p. 1539–1550.

    Google Scholar 

  12. Appelbaum PC: Antimicrobial resistance inStreptococcus pneumonias: an overview. Clinical Infectious Diseases 1992, 15: 77–83.

    PubMed  Google Scholar 

  13. Baquero F, Martinez-Beltran J, Loza E: A review of antibiotic resistance patterns ofStreptococcus pneumoniae in Europe. Journal of Antimicrobial Chemotherapy 1991, 28, Supplement C: 31–38.

    PubMed  Google Scholar 

  14. Klugman KP: Pneumococcal resistance to antibiotics. Clinical Microbiology Reviews 1990, 3: 171–196.

    PubMed  Google Scholar 

  15. Ericsson HM, Sherris JC: Antibiotic sensitivity testing. Report of an international collaborative study. Acta Pathologica et Microbiologica Scandinavica (B) 1971, Supplement 217: 1–90.

    Google Scholar 

  16. Forsgren A, Walder M: Antimicrobial susceptibility of bacteria isolated in South Sweden including a 13-year follow-up study of some respiratory tract pathogens. Acta Pathologica, Microbiologica, et Immunologica Scandinavica 1994, 102: 227–235.

    Google Scholar 

  17. Breiman RF, Butler JC, Tenover FC, Elliot JA, Facklam RR: Emergence of drug resistant pneumococcal infections in the United States. Journal of the American Medical Association 1994, 271: 1831–1835.

    PubMed  Google Scholar 

  18. Munoz R, Coffey TJ, Daniels M, Dowson CG, Laible G, Casal J, Hakenbeck R, Jacobs M, Musser JM, Spratt BG: Intercontinental spread of a multiresistant clone of serotype 23FStreptococcus pneumoniae. Journal of Infectious Diseases 1991, 164: 302–306.

    PubMed  Google Scholar 

  19. Linares J, Pallares A, Alonso T, Perez JL, Ayats J, Guidol F, Viladrich PF, Martin R: Trends in antimicrobial resistance of clinical isolates ofStreptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979–1990). Clinical Infectious Diseases 1992, 15: 99–105.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Bacteriology, Swedish Institute for Infectious Disease Control, S-10521, Stockholm, Sweden

    B. Olsson-Liljequist & B. M. Hoffman

  2. Danderyd Hospital, Stockholm, Sweden

    J. Hedlund

Authors
  1. B. Olsson-Liljequist
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. M. Hoffman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Hedlund
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Olsson-Liljequist, B., Hoffman, B.M. & Hedlund, J. Activity of trovafloxacin against blood isolates ofStreptococcus pneumoniae in Sweden. Eur. J. Clin. Microbiol. Infect. Dis. 15, 671–675 (1996). https://doi.org/10.1007/BF01691157

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01691157

Keywords

Search

Navigation